Urinary tract infection

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
2 Unique sponsors
5 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
J Anti-infectives (ATC J) 2
P Parasitology (ATC P) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Azole antifungal 1 substance
Phase III: 1 Phase II: 1 Phase I (Other): 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • Spero Therapeutics Inc. Commercial
    TEBIPENEM PIVOXIL HYDROBROMIDE
    2023-503785-22-00 9 countries 2024 n=1,454
    Ended

Phase II

1 trial
  • Pfizer Inc. Commercial
    AVIBACTAM SODIUM; AZTREONAM; AZTREONAM, AVIBACTAM SODIUM; METRONIDAZOLE
    2022-501575-12-00 4 countries 2023 n=20
    Recruiting

Phase I (Other)

1 trial
  • Pfizer Inc. Commercial
    IMP not specified
    2023-507117-10-00 1 country 2024 n=12
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Pfizer Inc. Commercial 2 Phase I (Other), Phase II 1
Spero Therapeutics Inc. Commercial 1 Phase III 0
New trials by year
2023
1
2024
2
← All indication landscapes